BiomEdit
Eric Young has extensive work experience in the field of business development and finance. Eric is currently serving as the Chief Business Officer at BiomEdit since March 2023. Prior to their current role, Eric held the position of Head of Business Development at Elanco from December 2020 to March 2023, where they led a team focused on strategic value creation initiatives and projects through innovative financial transactions and deal structures. Before joining Elanco, Eric had a long tenure at Eli Lilly and Company, where they served as the Head of Investment Management and Global Treasury in the Corporate Finance and Business Development division from July 2001 to December 2020. Additionally, Eric has also held the role of Member Investment Committee of the Board at the Indiana Biosciences Research Institute since September 2016. Throughout their career, Eric has been involved in various strategic transactions such as non-traditional M&A, licensing, JV partnerships, and divestitures, creating both near-term and future opportunities for the organizations they have worked with.
Eric Young has a Bachelor of Science (B.S.) degree in Finance from Indiana University - Kelley School of Business. Eric also holds a Master of Business Administration (MBA) degree in Finance from the same institution.
This person is not in any offices
BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.